- MediPharm Labs (LABS) has completed a medical cannabis export to Barbados in conjunction with partner Avicanna
- The company has manufactured and delivered Avicanna RHO Phyto products for the medical community and patients in the Caribbean
- MediPharm is the only North American producer with a Drug Establishment License (GMP) for the extraction of natural cannabinoids
- MediPharm Labs formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products to domestic and international markets
- MediPharm Labs Corp. (LABS) opened trading at C$0.225 per share
MediPharm Labs (LABS) has completed a medical cannabis export to Barbados in conjunction with partner Avicanna (TSX: AVCN).
“Our GMP platform make us the go-to partner for companies looking to access global medical cannabis programs,” said Bryan Howcroft, CEO, MediPharm Labs.
“As countries around the world continue to adopt medical cannabis programs, MediPharm Labs is best positioned to serve these markets as the only North American producer with a Drug Establishment License (GMP) for the extraction of natural cannabinoids.”
The company has manufactured and delivered Avicanna RHO Phyto products for the medical community and patients in the Caribbean through Bryden Stokes, an established health and pharmaceutical product distributor in the region.
These advanced cannabis products are marketed via the Avicanna educational platform, including patient support, marketing, and training.
MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms.
Through its wholesale and white label platforms, MediPharm Labs formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products to domestic and international markets.
MediPharm Labs Corp. (LABS) opened trading at C$0.225 per share.
